Lantern Pharma Inc. LTRN
Set alert
As of Nov 3, 9:59 AM ET
- YTD
- -77.89%
- 1 year
- -82.46%
- Open
- 0.6683
- Prev close
- 0.64
- Mkt cap
- 10.01M
- Vol
- 6.60K
- Avg vol
- 234.32K
- EPS
- -1.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.64
- High
- 0.67
- Forward P/E
- -1.50
- Beta
- 1.57
- Short ratio
- 4.74
- Inst. own
- 24.10%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.41
- 200-d avg
- 4.86
- 1y target
- 20.50
News
3 weeks ago gurufocus.com
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in
3 weeks ago businesswire.com
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to…
1 month ago businesswire.com
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering.
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved…
1 month ago businesswire.com
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop…
1 month ago seekingalpha.com
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
1 month ago gurufocus.com
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology t
1 month ago businesswire.com
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
DALLAS--(BUSINESS WIRE)--Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmark.
-
1 month ago benzinga.com
Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers
Lantern Pharma Inc. (NASDAQ:LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States…
1 month ago businesswire.com
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today…
1 month ago benzinga.com
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript
Lantern Pharma (NASDAQ:LTRN) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to…
1 month ago businesswire.com
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies,…
2 months ago seekingalpha.com
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.38) by 50 percent. This is a 42.5 percent decrease over losses of…
2 months ago businesswire.com
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.
2 months ago gurufocus.com
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (âAIâ) company developing targeted and transformative cancer therapies using its proprietary
2 months ago businesswire.com
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET.
3 months ago gurufocus.com
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and th
-
3 months ago benzinga.com
Lantern Pharma Creates Open-Medicine AI As Separate Entity
Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing…
3 months ago businesswire.com
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
DALLAS--(BUSINESS WIRE)--Open Medicine AI is launched as separate entity by Lantern Pharma.
-
3 months ago benzinga.com
Lantern Pharma Announces EMA Clearance Of An Investigator-Initiated Phase 1b/2 Clinical Trial Of LP-184 In Advanced, Recurrent Bladder Cancer
The study will be conducted at Rigshospitalet in Copenhagen — Denmark’s national referral center for urologic cancers — in collaboration with Professor Helle Pappot, MD, DMSc, a leading authority in…
3 months ago businesswire.com
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
DALLAS--(BUSINESS WIRE)--EMA Phase 1b/2 Clinical Trial for LP-184.
-
3 months ago benzinga.com
Lantern Pharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For 'Methods For The Treatment Of Solid Tumor Cancers Using Illudins And Biomarkers'
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers…
3 months ago businesswire.com
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today…
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $2.5 million. Tvardi Therapeutics…
-
3 months ago benzinga.com
Lantern Pharma Launches ZetaOmics, A Computational-Biology Module Of Its WithZeta.ai Co-Scientist Platform
ZetaOmics introduces an autonomous "Computational Biologist" persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for…
3 months ago businesswire.com
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its…
5 months ago gurufocus.com
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today reported clinical data and updates in the form of a presentation from its on
-
5 months ago benzinga.com
Lantern Pharma Reports Clinical Data And Updates From Ongoing Phase 2 HARMONIC Trial Evaluating LP-300 In Combination With Carboplatin And Pemetrexed In Patients With EGFR Exon 21 L858R-Mutant NSCLC
Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile.PFS benefit deepens…
5 months ago businesswire.com
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
DALLAS--(BUSINESS WIRE)--Harmonic Presentation in form of 8K.
-
5 months ago benzinga.com
Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma
In its written responses to Lantern's Type C meeting request, the FDA raised no objections to key proposed protocol amendments, providing a more focused, clearer regulatory path forward for the…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
5 months ago benzinga.com
Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 28.57 percent increase over losses of…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
5 months ago benzinga.com
Lantern Pharma Announces Up To $9.25M Direct Offering With Existing Shareholders And Unnamed Institutional Investor; Transaction Expected To Close May 14
Lantern Pharma announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,135,923 shares of its common stock (or pre-funded warrants in lieu thereof) at…
-
6 months ago benzinga.com
Lantern Pharma Expands Its predictBBB.ai Web Service Into A Large Quantitative Model
For the first time, pharmaceutical scientists and medicinal chemists can access a unified, benchmark-validated LQM — not as a batch software installation, not as a siloed cheminformatics tool — but…
-
6 months ago benzinga.com
Lantern Pharma Plans First Public Demonstration Of withZeta.ai, Its Multi-Agentic AI Co-Scientist Platform On April 30
The event follows the platform's scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks the…
-
6 months ago benzinga.com
Lantern Pharma Schedules FDA Type C Meeting To Refine HARMONIC Trial For LP-300 In EGFR L858R NSCLC, Highlighting Progression-Free Survival Signals
Lantern Pharma Schedules Type C Meeting with the FDA to Advance HARMONIC™ Protocol Amendments Targeting This High-Need Population, Reflecting LP-300's Novel Mechanism of Action and the Rapidly…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
7 months ago benzinga.com
Lantern Pharma Q4 EPS $(0.36) Beats $(0.46) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21.74 percent. This is a 33.33 percent increase over losses of…
7 months ago benzinga.com
Why Is Lantern Pharma Stock Soaring Monday?
Lantern Pharma shares rebound in premarket trading as the company debunks a false report regarding CEO Panna Sharma's departure.
-
7 months ago benzinga.com
Earnings Scheduled For March 30, 2026
Earnings Scheduled For March 30, 2026
7 months ago benzinga.com
Why PMGC Holdings Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
PMGC Holdings shares surged 100.6% to $3.35 in pre-market trading after announcing a licensing agreement amendment for its clinical development program. Gainers include ITRM, ZNB, and GV; Losers…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
7 months ago benzinga.com
Lantern Pharma And Starlight Therapeutics Say FDA Clears IND Application For STAR-001 In Planned Phase 1 Pediatric Clinical Trial
The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM,…
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session